Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
would they only go that much? 1.80? They run the risk of dropping below again won't they? Unless they have some amazing news coming right after like a partnership maybe. We shall see
I don't think they will do that much. I think it will be around 1 for 20. With 1 for 20 that would be a $5.30 share price and the outstanding shares would be 4 mil shares outstanding. Gotta have some liquidity in there.
no, not yet. That will be determined by management when they do the reverse split. anywhere between 1 for 2 or up to 1 for 40.
About one year ago they did a 1 for 150 reverse split and from there $8 per share came down to where it is now at .04 cents per share
I agree with you!!!
The question is we don't know who these biotech companies that are interested are? They could be small bio or they could be big pharma. Unfortunately it is not in the best interest for shareholders to know until a deal is done. The CEO is probably close to a deal, unfortunately these deals with all legal matters, and contracts and talks take time to complete. Therefore it may not get done before the need for a reverse split. I rather the company negotiate a good deal with strength then hash a bad deal in an attempt to get the share price above $1.
JP I missed your analysis over the weekend. Glad you are back. You tell the truth. You are right the convertible shares have destroyed this stock. You can look at all other biotechs with toxic financing preferred shares are a huge burden on the share price. Always is and will always be that way!
The fact that he said over the last 6 months partnership interest has tripled is a good thing. Geert also stated that he couldn't go into any detail because of current talks and it wouldn't be fair to shareholders nor the companies he is in talks with. I think that Geert can get a deal done. Of course a higher share price would help even more in that regards. Plus you are right RXII has a lot of catalysts they are going to show scar results again for the 7 months when they do a preliminary analysis with photographs and data. Because the scar data shown improved from 3 months to 6 months then the 7 to 9 months should be even better.
New PR this morning from Rxi for patent issuance for scar product RXI-109
RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications
http://finance.yahoo.com/news/rxi-pharmaceuticals-strengthens-intellectual-property-110200765.html
I agree, all seems like it is moving along nicely.
Looks like Josh Sason got freaked out by the lawsuit. Now he knows the SEC is probably after him and other attorney's. He's probably selling any trace of the amarantus deal. He will dump all his shares now in AMBS
Josh sason? We already know he's a crook
Look at Josh Sason's reply:
"We continue to stand steadfastly behind Gerald and behind Amarantus. We've worked together with the company since 2010 in various different contexts and are confident in the future. To that end, we continue to act in the best interests of value creation and support the company in furthering its initiatives to achieve true value for us, for you and for all involved"
I can't believe that he would type that with a straight face. His toxic financing has ruined AMBS and he says he believes in the company prospects. If that was true he wouldn't be selling shares for profit every chance he got.
But I must say while I do Applaud that shareholder for writing and doing something, she is writing to a crook. He is not gonna care nor admit that he is converting shares. That's what toxic financing does they sell quick to make a profit. They profit off of struggling companies to make millions of dollars.
RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference
http://finance.yahoo.com/news/rxi-pharmaceuticals-present-oligonucleotide-therapeutics-110200996.html
Holy smokes JPtronic forget that they haven't recruited participants yet look how long the phase 2 study is expected to take?
It is showing a completion date of 2019:
Estimated Enrollment: 10
Study Start Date: April 2016
Estimated Study Completion Date: July 2020
Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)
3 years for a 10 patient trial? and the study hasn't even started yet, I'm sure the completion date will be pushed up. In the meanwhile shareholders will have further losses to look forward too.
He said sufficient to carry the company through 2016, he didn't mention his 200k salary pay other executives pay.
I'm sorry to say but investors got scammed here. They put up the mantra of MANF as being good science so a majority of people invested based off of that one product. Although they peddled other things they bought to keep investors in so they could dilute shares and keep a nice paycheck for themselves. Plus the board of directors will never fire the CEO? AFter all Gerald's father is on the board of directors, he would not fire his own son. That means investors can look forward to more losses.
I think their is a breach of duty when the board of directors refuse to take action and fire Gerald. Although, this will never happen as long as his father is on the BOD.
The sad part? Those toxic financers actually are making money selling AMBS shares down here. It's the shareholders that are getting screwed
Seems like your prediction is coming True ZeusGreek. AMBS is tanking by teh minute with floorless toxic convertibles. Opa na exis kali mera! Greek for " hoorah, have a nice day"
Right here on Bloomberg in the link below: It shows Gerald Commissiong obtaining $658,000 salary compensation
http://www.bloomberg.com/research/stocks/people/person.asp?personId=54614600&privcapId=54426315
Oh I agree where is the lympro revenue that was promised by 2015. Also where is the CLIA certification for Lympro? All was just a show to boost share price so CEO could dilute more.
Check out the new PR Geert may have a trick up his sleeve yet. It says Rxi will post financial results on March 30, 2016 which they have done in many PRs but read what comes afterwards..
a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2015, and provide a business update on Wednesday, March 30, 2016 after the close of the U.S. financial markets.
" provide a business update on Wednesday, March 30, 2016 after the close of the U.S. financial markets."
I would like to know what type of business update this is? possible partnership? I'm intrigued
I voted "for" the reverse split. The NASDAQ is better and after the reverse split institutions will be able to get in. The OTC would be disastrous and the share price would linger IMO.
I'm glad that there are people out their in the world looking out for others not to lose money in AMBS.
JP now that you bring that up I can see how this is playing out. GC the CEO needs to be held accountable. Any other CEO with this type of poor management would have been canned a long time ago.
Look at Sarepta Therapeutics, they canned the CEO when they saw he couldn't work with the FDA.
The big problem with AMBS is that Gerald's father is on the board of directors and as long as he is there Gerald is staying. If the board of directors were really doing their job they would have fired Gerald a long time and replaced him with another CEO. unfortunately this will continue to go down the drain.
I hope you make your money back, but maybe not if this is a scam company. CEO is so shady. The sad part is another 150 to 1 reverse split would give you 26 shares left in the end of AMBS
I agree well said
But AMBS didn't uplist to NASDAQ. It remained on the OTC. Also the CEO of AMBS is a crook and has signed terrible toxic conversions.
Wrong it changes a lot.
Because right now the float for RXII is 60 million shares outstanding. With Reverse split depends what they do but for example lets say 1 for 20 that would bring the shares outstanding to 4 million shares, very small float. No way short sellers would short a stock with only a 4 mil share float.
Thank you for your factual post. That shows the truth about what really occurs with these OTC companies that get toxic financing from that guy.
One or two shorters is okay, but so many coming is not a good thing. It means toxic shares will drag this lower!
And it has one full time-employee.... doesn't this bother anyone?
Any reason on company being so quiet lately? Just nothing to report? No PR since Jan 26th. I hope RXII has something good coming up for the huge silence
Quarter 4 2017 launch for revenue? That's like 2 years from now? Why so long? Ouch no way AMBS goes positive tomorrow, it will go negative.
Oh I agree with you JP. First of all AMBS needs to stop buying assets every 2 years. they are just stringing people along. They should focus on what they have. If I were CEO I would only have kept two important assets Lympro going forward with CLIA and getting Eltoprazine to phase 3 as quick as possible. Reasons?
With Eltoprazine being put through phase 2 and close to phase 3 it is easier to get non-dilutive funding. Thus in turn get away from toxics. Remember Eltoprazine They should have put more focus on an already later stage asset.
Now they are behind and they haven't even started the trial yet for ESS. Gerald says soon they are, but can we believe anything he says? It all looks like a disaster from here on out. JP thanks for your insight and being truthful and not sugarcoating anything. Just factual info and exposing Gerald for the liar he is.
Edit correction: Possible correction I'm now seeing that Elto trials may not have yet started either. Correct me if I'm wrong but if Eltoprazine trial hasn't started yet then what is the AMBS team along with gerald doing? Nothing?
No idea but the bid was up there. Low volume we will have to wait and see tomorrow I guess?
That's true Gerald will sell out his shareholders all so he can keep a paycheck. He will dump all those shares in the market and this will go lower. The other day with the PR was another stunt to pump the stock so the financiers can dump more shares. Poor shareholders still being fleeced just sad to watch
They tried to drag it down they took it down by 7% and it finished the day up 1%. Someone on the other side was buying heavy all those sales and shorts coming through.
I'm sure first they will try to get non-dilutive financing. We shall have to wait and see. Although RXII is still in good shape and I think the fact they are pushing cosmecueticals bodes well for the future of the company. Remember they don't need FDA approval to start selling cosmecueticals, they also don't need multiple trials. All they need is delivery which is microneedling they are working on and then consumer testing and they can start generating revenue.
Looking out a few years from now if the cosmeceuticals and scar trials are successful this company will probably be bought out by Johnson & Johnson or trade higher.
If you find losing money in AMBS fun then Enjoy!!!!